Yedida Y Bogachkov PhD,  —

In a subset of patients with mild to moderate Alzheimer’s and evidence of severe gum disease due to P. gingivalis infection, treatment with atuzaginstat (COR388) appeared to slow their cognitive decline, according to results from the Phase 2/3 GAIN clinical trial. Across all treated study patients, however, atuzaginstat’s use over about one year failed…

Athira Pharma has completed enrollment in its ACT-AD Phase 2 trial evaluating the safety and efficacy of ATH-1017 in adults with mild-to-moderate Alzheimer’s disease. “The completion of enrollment in our ACT-AD trial is an important step forward in advancing ATH-1017 as a potential new treatment option for patients…

Eisai has started work on a rolling submission to the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for lecanemab (BAN2401), its antibody treatment for early Alzheimer’s disease. As a rolling submission, Eisai will submit each portion of its application as it is completed,…

Athira Pharma, Inc will initiate an open-label extension study for two ongoing clinical trials investigating ATH-1017 to treat Alzheimer’s disease. Both clinical trials — the Phase 2/3 LIFT-AD (NCT04488419) and Phase 2 ACT-AD (NCT04491006) — are investigating ATH-1017, a small molecule designed to enhance the effect of hepatocyte growth…

People affected by Alzheimer’s disease and related dementias are invited to register for the Mayo Clinic Conference on Brain Health and Dementia, which also pays tribute to all that the community has been going through during the COVID-19 pandemic. Held virtually on Oct. 29 from 9:15am to 2:15pm…

Amyloid-beta produced in peripheral organs, specifically the liver, may be implicated in the brain neurodegeneration observed in Alzheimer’s disease, according to a mouse study. The study, “Synthesis of human amyloid restricted to liver results in an Alzheimer disease–like neurodegenerative phenotype,” was published in PLOS Biology. Deposits of amyloid-beta…

Research institutions in North Carolina and Texas have become the newest members of a national network of Alzheimer’s Disease Research Centers (ADRCs), which are at the forefront of research into Alzheimer’s and related dementias. The ADRCs, a project funded by the National Institute on Aging (NIA), have…